Alto Neuroscience (NYSE:ANRO) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Alto Neuroscience has received a "sell (D-)" rating from Weiss Ratings, while other analysts provide mixed reviews with reports of "buy" ratings and increased price targets up to $50.00.
• Currently, Alto Neuroscience's stock price is at $11.11, with a consensus target price of $19.00 and a market cap of approximately $300.97 million.
• The company recently reported a quarterly earnings miss, posting a loss of ($0.65) per share, which was lower than analysts' expectations of ($0.57).

Alto Neuroscience (NYSE:ANRO - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

ANRO has been the subject of several other research reports. Robert W. Baird raised their price target on Alto Neuroscience from $10.00 to $16.00 and gave the company an "outperform" rating in a report on Monday. Chardan Capital assumed coverage on Alto Neuroscience in a report on Monday, September 29th. They set a "buy" rating and a $15.00 price target for the company. Finally, HC Wainwright increased their price objective on Alto Neuroscience from $10.00 to $50.00 and gave the stock a "buy" rating in a research report on Friday. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.

Alto Neuroscience Stock Down 0.6%

NYSE:ANRO traded down $0.07 during trading hours on Friday, reaching $11.11. 294,817 shares of the stock were exchanged, compared to its average volume of 645,050. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $12.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The firm has a 50 day moving average of $4.88 and a 200 day moving average of $3.36. The stock has a market cap of $300.97 million, a PE ratio of -4.66 and a beta of 2.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08). On average, equities analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Montreal Can bought a new stake in shares of Alto Neuroscience during the second quarter worth about $25,000. Ground Swell Capital LLC bought a new stake in shares of Alto Neuroscience during the second quarter worth about $27,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Alto Neuroscience during the second quarter worth about $33,000. AlphaCore Capital LLC grew its holdings in shares of Alto Neuroscience by 100.0% during the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company's stock worth $44,000 after purchasing an additional 10,000 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience in the first quarter worth approximately $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.